drugset / Trial / NCT05059912
CD7 CAR T-cell for R/R CD7+ T Cell Lymphoma
Phase 2
Unknown
20 enrolled
The First Affiliated Hospital of Soochow University
Affiliated Hospital of Jiangnan University · collabAffiliated Zhongshan Hospital of Dalian University · collabPersonGen BioTherapeutics (Suzhou) Co., Ltd. · collabThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · collabThe First Affiliated Hospital of Dalian Medical University · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, open-label, multiple center and single arm phase 2 study to evaluate the efficacy and safety of T cells expressing humanized CD7 chimeric antigen receptors treatment for patients with refractory/relapsed CD7 positive T cell lymphoma.
Timeline
- Start
- 2021-08-05
- Primary completion
- 2023-08-03
- Completion
- 2024-08-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Humanized CD7 CAR-T cells | Cell therapy | 500000 cells/kg | Intravenous |
| Subject | Humanized CD7 CAR-T cells | Cell therapy | 5e+06 cells/kg | Intravenous |